References

ometendo

Ожирение и метаболизм

Obesity and metabolism

2071-87132306-5524

Endocrinology Research Centre

10.14341/2071-8713-5239

ometendo-5239

Research Article

Статьи

Articles

Метаболический синдром как протромбогенное состояние

Metabolic syndrome as a prothrombogenic state

Berkovskaya

M A

abaita@rambler. ru

Butrova

S A

2009

15092009

№3 (2009)

2009

Berkovskaya M.A., Butrova S.A.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.omet-endojournals.ru/jour/article/view/5239

В настоящее время ожирение достигло масштабов эпидемии. Наиболее неблагоприятным является абдоминальное ожирение, взаимосвязанное с комплексом факторов и маркеров риска сердечно-сосудистых заболеваний (ССЗ) и сахарного диабета 2 типа (СД2) - метаболическим синдромом (МС). МС ассоциирован также с риском атеротромбоза, поскольку характеризуется как нарушением фибринолиза, так и протромбогенными сдвигами коагуляционного и тромбоцитарного звеньев гемостаза. Обзор освещает механизмы нарушения гемостаза при МС, что расширяет научные представления о патогенезе ССЗ.

The prevalence of obesity has reached epidemic proportions nowadays. Abdominal obesity is the most unfavorable one, because of its association with the complex of markers and risk factors ofcardiovascular diseases and type 2 diabetes mellitus, which is called metabolic syndrome (MS). MS also increases risk of atherothrombosis because it is characterized by low fibrinolysis and prothrombogenic changes in coagulation and platelet hemostasis. The review highlights the mechanisms of hemostatic disturbances in MS, which eхends our scientific knowledge about pathogenesis of cardio vascular diseases

ожирениеметаболический синдроминсулинорезистентностьпротромбогенное состояниефибри-нолизингибитор активатора плазминогена 1 типа

obesitymetabolic syndromeinsulin resistanceprothrombogenic statefibrinolysisplasminogen activator ingibitor-1

References1

Juhan-Vague I., Alessi M.C., Vague P. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia. 1991; 34: 457-62.

Баркаган З.С., Момот А.П. Основы диагностики нарушений системы гемостаза. - М.: «Ньюдиамед-АО», 1999. - 224 с.

Wannamethee S.G., Lowe G.D., Shaper A.G., Rumley A., Lennon L., Whincup P.H. The metabolic syndrome and insulin resistance: relationship to haemostatic and inflammatory markers in older non-diabetic men. Atherosclerosis. 2005 Jul;181(1):101-8.

Sakkinen P.A., Wahl P., Cushmann M., Lewis M.R., Tracy R.P. Clustering of procoagulation, inflammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am. J. Epidemiol 2000; 152:897-907.

Devaraj S., Rosenson R.S., Jialal I. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol. Metab. Clin. North. Am. 2004; Jun; 33(2):431-53.

Moyer M.P., Tracy R.P., Tracy P.B., van't Veer C, Sparks C.E., Mann K.G. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arteriosclerosis Thromb. Vasc. Biol. 1998; 18:458-65.

Heywood D.M., Mansfield M.W., Grant P.J. Factor VII gene polymorphisms, factor VII: С levels and features of insulin resistance in non-insulindependent diabetes mellitus. Thromb. Haemost. 1996; 75:401-6.

Mansfield M.W., Heywood D.M., Grant P.J. Circulating levels of factor VII, fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree relatives of patients with NIDDM. Circulation 1996; 94:2171-6.

Miller G.J. Lipoprotein and thrombosis: effects of lipid lowering. Curr Pin Lipidol 1995;6:38-42.

Agewall S., Bokemark L.Wkstrand J., Lindahl A, Fagerberg B. Insulin sensitivity and hemostatic factors i n clinically healthy 58-year-old men. Thromb. Haemost. 2000; 84:571-5.

Nieuwdorp M., Stroes E.S., Meijers J.C., Buller H. Hypercoagulability in the metabolic syndrome. Curr. Opin. Pharmacol. 2005; Apr; 5(2):155-9.

Bahia L, Aguiar L.G., Villela N., Bottino D., Godoy-Matos A.F., Geloneze В., Tambascia M., Bouskela E. Relationship between adipokines, inflammation, and vascular reactivity in lean controls and obese subjects with metabolic syndrome. Clinics. 2006; Oct; 61(5):433-40.

Kahn S.E., Zinman В., Haffner S.M., O'Neill M.C., Kravitz B.G., Yu D., Freed M.I., Herman W.H., Holman R.R., Jones N.P., Lachin J.M., Viberti G.C.; ADOPT Study Group. Obesity is a major determinant of the association of C-reactive protein levels and the metabolic syndrome in type 2 diabetes.: Diabetes. 2006 Aug; 55(8):2357-64.

Ay C., Tengler T., Vormittag R., Simanek R., Dorda W., Vukovich Т., Rabinger I. Venous thromboembolism-a manifestation of the metabolic syndrome. Haematologica. 2007 Mar; 92(3):374-80.

Ragab A., Abousamra N.K., Higazy A., Saleh 0. Relationship between Insulin Resistance and Some Coagulation and Fibrinolytic Parameters in Patients with Metabolic Syndrome. Lab. Hematol. 2008; 14(1):1-6.

Warner D., Mansfield M.W., Grant P.J. Coagulation factor XIII and cardiovascular disease in UK Asians patients undergoing coronary angiography. Ttiromb. Haemost. 2001;85:408-11.

Cucuianu M., Dican L. Coagulation factor XIII and atherothrombosis. A mini-review. Rom. J. Intern. Med. 2003; 41(4):339-55.

Kohler H.P., Mansfield M.W., Clark P.S., Grant P.J. Interaction between insulin resistance and factor XIIIVal34Leu in patients with coronary artery disease. Ttiromb. Haemost. 1999;82:1202-3.

Kohler H.P., Grant P.J. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med. 2000; 342:1792-801.

Sobel B.E., Taatjes D.J., Schneider D.J. Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1979-89.

Juhan-Vague I., Руке S.D.M., Alessi M.C., Jespersen J., Haverkate F., Thompson S.G. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation. 1996; 94: 2057-63.

Collet J.P., Montalescot G., Vicaut E., Ankri A, Walylo F., Lesty C., Choussat R ., Beygui F., Borentain M., Vignolles N., Thomas D. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation. 2003; 108:391-4.

Smith A., Patterson C., Yarnell J., RumleyA., Ben-Shlomo Y., Lowe G. Which hemostatic markers add to the predictive value of conventional riskfactors for coronary heart disease and ischemic stroke? The Caerphilly Study. Circulation. 2005; 112: 3080-7.

De Maat M.P., Bladbjerg E.M., Drivsholm Т., Borch-Johnsen K., Moller L, Jespersen J. Inflammation, thrombosis and atherosclerosis: results of the Glostrup study. J. Thromb. Haemost. 2003; 1: 950-7.

Anand S.S., Yi Q., Gerstein H., Lonn E., Jacobs R., Vuksan V., Teo K., Davis В., Montague P., Yusuf S. Study of Health Assessment and Risk in Ethnic Groups; Study of Health Assessment and Risk Evaluation in Aboriginal Peoples Investigators. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardi ovascular disease. Circulation. 2003; 108:420-5.

Dentali F., Romualdi E., Ageno W. The metabolic syndrome and the risk of thrombosis. Haematologica. 2007 Mar; 92(3):297-9.

Juhan-Vague I., Alessi M.C., Mavri A., Morange P.E. Plasminogen activator inhibitor-1 , inflammation, obesity, insulin resistance and vascular risk. J. Thromb. Haemost. 2003;1:1575-9.

Ingelsson E., Pencina M.J., Tofler G.H., Benjamin E.J., Lanier K.J., Jacques P.F., Fox C.S., Meigs J.B., Levy D., Larson M.G., Selhub J., D'Agostino R.B. Sr, Wang T.J., Vasan R.S. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007 Aug 28; 116(9):984-92.

Folsom A.R., Qamhieh H.T., Wing R.R., Jeffery R.W., Stinson V.L., Kuller L.H., Wu K.K. Impact of weight loss on plasminogen activator inhibitor (PAI-1), factor VII, and other hemostatic factors in moderately overweight adults. Arterioscler. Thromb. 1993; 13:162-9.

Trost S., Pratley R., Sobel B. Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type II diabetes. Curr Diab Rep. 2006; 6:47-54.

Ihara H., Urano Т., Takada A., Loskutoff D.J. Induction of plasminogen activator inhibitor 1 gene expression in adipocytes by thiazolidinediones. FASEB J. 2001; 15: 1233-5.

Voros G., Maquoi E., Collen D., Lijnen H.R. Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-alpha, TNF-alpha converting enzyme and ADAMTS family members in murine fat territories. Biochim. Biophys. Acta. 2003; 1625: 36-42.

Bastelica D., Morange P., Berthet В., Borghi H., Lacroix O., Grino M., Juhan-Vague I., Alessi M.C. Stromal cells are the main plasminogen activator inhibitor-1 producing cells in human fat: evidence of differences between visceral and subcutaneous deposits. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 173-8.

Fain J.N., Madan A.K., Hiler Ml., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology. 2004; 145: 2273-82.

Alessi M.C, Bastelica D., Mavri A., Morange P., Berthet В., Grino M., Juhan-Vague I. Plasma PAI-1 levels are more strongly related to liver steatosis than to adipose tissue accumulation. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 1262-8.

Alessi M.C., Juhan-Vague I. PAI-1 and the metabolic syndrome: links, causes, and consequences. Arterioscler. Thromb. Vasc. Biol. 2006 Oct; 26(10): 2200-7.

Ayachi S.E., Paulmyer-Lacroix O., Verdier M., Alessi M.C, Dutour A., Grino M. 11 beta-Hydroxysteroid dehydrogenase type 1-driven cortisone reactivation regulates plasminogen activator inhibitor type 1 in adipose tissue of obese women. J. Thromb. Haemost. 2006; 4: 621-7.

Festa A., Williams K., Tracy R.P., Wagenknecht L.E., Haffner S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type II diabetes. Circulation. 2006; 113: 1753-9.

Lopez-Alemany R., Redondo J.M., Nagamine Y., Munoz-Canoves P. Plasminogen activator inhibitor type-1 inhibits insulin signaling by competing with alphavbeta3 integrin for vitronectin binding. Eur. J. Biochem. 2003; 270: 814-21.

Lijnen H.R., Maquoi E., Morange P., Voros G., Van Hoef В., Корр F., Collen D., Juhan-Vague I., Alessi M.C. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler. Thromb. Vasc. Biol. 2003; 23: 78-84.

Kohler H.P. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss. Med. Wkly. 2002 May 18; 132(19-20): 241-52.

Westerbacka J., Yki-Jarvinen H., Turpeinen A., Rissanen A., Vehkavaara S., Syrjala M., Lassila R. Inhibition of platelet-collagen interaction. An in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 167-72.

Kotani K., Sakane N., Saiga K., Mu H., Kurozawa Y. Clustered components of the metabolic syndrome and platelet counts in Japanese females. Clin. Chem. Lab. Med. 2007; 45(3):3 76-9.

The authors declare that there are no conflicts of interest present.